SuperworthSpero Therapeutics EPS SPRO
Diluted earnings per share by quarter and over the last twelve months, from 2016.
- Last 12 months, to Jun 30, 2026
- $0.11
- Latest quarter, Q2 FY26
- −$0.16
- Fiscal year 2025
- $0.12
Spero Therapeutics' earnings per share was $0.11 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.16.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.12 | n/a |
| FY2024 | −$1.27 | −402% |
| FY2023 | $0.42 | +68% |
| FY2022 | $0.25 | n/a |
| FY2021 | −$2.89 | n/a |
| FY2020 | −$3.61 | n/a |
| FY2019 | −$3.29 | n/a |
| FY2018 | −$2.63 | n/a |
| FY2017 | −$95.42 | n/a |
| FY2016 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.16 | n/a | $0.11 | |
| Q1 FY26 | −$0.13 | n/a | $0.24 | |
| Q4 FY25 | $0.53 | n/a | $0.12 | |
| Q3 FY25 | −$0.13 | n/a | −$0.79 | |
| Q2 FY25 | −$0.03 | n/a | −$0.98 | |
| Q1 FY25 | −$0.25 | n/a | −$1.28 | |
| Q4 FY24 | −$0.38 | −140% | −$1.27 | |
| Q3 FY24 | −$0.32 | n/a | $0.07 | |
| Q2 FY24 | −$0.33 | n/a | $0.33 | |
| Q1 FY24 | −$0.24 | n/a | $0.43 | |
| Q4 FY23 | $0.96 | −61% | $0.42 | |
| Q3 FY23 | −$0.06 | n/a | $1.92 |
Against its peers
Companies in Drug Manufacturers - General nearest Spero Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Spero Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.